celiprolol has been researched along with Aneurysm, Ruptured in 2 studies
Celiprolol: A cardioselective beta-1 adrenergic antagonist that has intrinsic sympathomimetic activity. It is used in the management of ANGINA PECTORIS and HYPERTENSION.
Aneurysm, Ruptured: The tearing or bursting of the weakened wall of the aneurysmal sac, usually heralded by sudden worsening pain. The great danger of a ruptured aneurysm is the large amount of blood spilling into the surrounding tissues and cavities, causing HEMORRHAGIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients with clinical vascular Ehlers-Danlos syndrome were randomly assigned to 5 years of treatment with celiprolol or to no treatment." | 9.14 | Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. ( Boutouyrie, P; Bozec, E; Collignon, P; De Backer, J; De Paepe, A; Emmerich, J; Fauret, AL; Fiessinger, JN; Georgesco, G; Germain, DP; Hulot, JS; Jeunemaitre, X; Laurent, S; Ong, KT; Perdu, J; Plauchu, H, 2010) |
| " Patients with clinical vascular Ehlers-Danlos syndrome were randomly assigned to 5 years of treatment with celiprolol or to no treatment." | 5.14 | Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. ( Boutouyrie, P; Bozec, E; Collignon, P; De Backer, J; De Paepe, A; Emmerich, J; Fauret, AL; Fiessinger, JN; Georgesco, G; Germain, DP; Hulot, JS; Jeunemaitre, X; Laurent, S; Ong, KT; Perdu, J; Plauchu, H, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brooke, BS | 1 |
| Ong, KT | 1 |
| Perdu, J | 1 |
| De Backer, J | 1 |
| Bozec, E | 1 |
| Collignon, P | 1 |
| Emmerich, J | 1 |
| Fauret, AL | 1 |
| Fiessinger, JN | 1 |
| Germain, DP | 1 |
| Georgesco, G | 1 |
| Hulot, JS | 1 |
| De Paepe, A | 1 |
| Plauchu, H | 1 |
| Jeunemaitre, X | 1 |
| Laurent, S | 1 |
| Boutouyrie, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Vascular Complications by BetaBlocker Treatment in Vascular Ehlers-Danlos Syndrome[NCT00190411] | Phase 4 | 54 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial.[NCT02597361] | Phase 3 | 61 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for celiprolol and Aneurysm, Ruptured
| Article | Year |
|---|---|
Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.
Topics: Adolescent; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aneurysm, Ruptured; Aortic | 2010 |
Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.
Topics: Adolescent; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aneurysm, Ruptured; Aortic | 2010 |
Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.
Topics: Adolescent; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aneurysm, Ruptured; Aortic | 2010 |
Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.
Topics: Adolescent; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aneurysm, Ruptured; Aortic | 2010 |
1 other study available for celiprolol and Aneurysm, Ruptured
| Article | Year |
|---|---|
Celiprolol therapy for vascular Ehlers-Danlos syndrome.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aneurysm, Ruptured; Aortic Dissection; Celipr | 2010 |